Gilead Sciences
Quarterly and annual revenue from company filings.
Business lines and operating measures.
Reported quarterly Total HIV revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 30, 2026From Apr 1, 2026 | 5,693,000,000 | Filed Aug 6, 2026 |
| Mar 31, 2026From Jan 1, 2026 | 5,030,000,000 | Filed May 7, 2026 |
| Jun 30, 2025From Apr 1, 2025 | 5,088,000,000 | Filed Aug 6, 2026 |
| Mar 31, 2025From Jan 1, 2025 | 4,587,000,000 | Filed May 7, 2026 |
Reported quarterly Total Liver Disease revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 30, 2026From Apr 1, 2026 | 877,000,000 | Filed Aug 6, 2026 |
| Mar 31, 2026From Jan 1, 2026 | 767,000,000 | Filed May 7, 2026 |
| Jun 30, 2025From Apr 1, 2025 | 795,000,000 | Filed Aug 6, 2026 |
| Mar 31, 2025From Jan 1, 2025 | 758,000,000 | Filed May 7, 2026 |
Reported quarterly Total Oncology revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 30, 2026From Apr 1, 2026 | 873,000,000 | Filed Aug 6, 2026 |
| Mar 31, 2026From Jan 1, 2026 | 810,000,000 | Filed May 7, 2026 |
| Jun 30, 2025From Apr 1, 2025 | 849,000,000 | Filed Aug 6, 2026 |
| Mar 31, 2025From Jan 1, 2025 | 757,000,000 | Filed May 7, 2026 |
Independent series; they may overlap and do not form an additive breakdown.
In 2025, we also received regulatory approvals or authorizations from FDA and European Commission for new products and expanded indications of our products, including: Product Regulatory Approval or Authorization Yeztugo/Yeytuo FDA granted approval for Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP.
Product Candidates in Virology Product Candidates Description Regulatory Filings Bulevirtide A Biologics License Application has been filed with FDA for bulevirtide for the treatment of chronic hepatitis delta virus (“HDV”) infection.
| Fiscal quarter | Ended | Total revenueUSD millions |
|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | 7,803, +12.1% versus FY 2026 Q1 |
| FY 2026 Q1 | Mar 31, 2026 | 6,960, −12.2% versus FY 2025 Q4 |
| FY 2025 Q4 | Dec 31, 2025 | 7,925, +2.0% versus FY 2025 Q3 |
| FY 2025 Q3 | Sep 30, 2025 | 7,769, +9.7% versus FY 2025 Q2 |
| FY 2025 Q2 | Jun 30, 2025 | 7,082, +6.2% versus FY 2025 Q1 |
| FY 2025 Q1 | Mar 31, 2025 | 6,667, −11.9% versus FY 2024 Q4 |
| FY 2024 Q4 | Dec 31, 2024 | 7,569, +0.3% versus FY 2024 Q3 |
| FY 2024 Q3 | Sep 30, 2024 | 7,545, +8.5% versus FY 2024 Q2 |
| FY 2024 Q2 | Jun 30, 2024 | 6,954, +4.0% versus FY 2024 Q1 |
| FY 2024 Q1 | Mar 31, 2024 | 6,686, −6.0% versus FY 2023 Q4 |
| FY 2023 Q4 | Dec 31, 2023 | 7,114, +0.9% versus FY 2023 Q3 |
| FY 2023 Q3 | Sep 30, 2023 | 7,051, +6.8% versus FY 2023 Q2 |
| FY 2023 Q2 | Jun 30, 2023 | 6,599, +3.9% versus FY 2023 Q1 |
| FY 2023 Q1 | Mar 31, 2023 | 6,352, −14.0% versus FY 2022 Q4 |
| FY 2022 Q4 | Dec 31, 2022 | 7,389, +4.9% versus FY 2022 Q3 |
| FY 2022 Q3 | Sep 30, 2022 | 7,042, +12.5% versus FY 2022 Q2 |
| FY 2022 Q2 | Jun 30, 2022 | 6,260, −5.0% versus FY 2022 Q1 |
| FY 2022 Q1 | Mar 31, 2022 | 6,590, −9.0% versus FY 2021 Q4 |
| FY 2021 Q4 | Dec 31, 2021 | 7,244, −2.4% versus FY 2021 Q3 |
| FY 2021 Q3 | Sep 30, 2021 | 7,421, +19.4% versus FY 2021 Q2 |
| FY 2021 Q2 | Jun 30, 2021 | 6,217, −3.2% versus FY 2021 Q1 |
| FY 2021 Q1 | Mar 31, 2021 | 6,423, −13.4% versus FY 2020 Q4 |
| FY 2020 Q4 | Dec 31, 2020 | 7,421, +12.8% versus FY 2020 Q3 |
| FY 2020 Q3 | Sep 30, 2020 | 6,577, +27.9% versus FY 2020 Q2 |
| FY 2020 Q2 | Jun 30, 2020 | 5,143, −7.3% versus FY 2020 Q1 |
| FY 2020 Q1 | Mar 31, 2020 | 5,548, −5.6% versus FY 2019 Q4 |
| FY 2019 Q4 | Dec 31, 2019 | 5,879, +4.9% versus FY 2019 Q3 |
| FY 2019 Q3 | Sep 30, 2019 | 5,604, −1.4% versus FY 2019 Q2 |
| FY 2019 Q2 | Jun 30, 2019 | 5,685, +7.7% versus FY 2019 Q1 |
| FY 2019 Q1 | Mar 31, 2019 | 5,281, −8.9% versus FY 2018 Q4 |
| FY 2018 Q4 | Dec 31, 2018 | 5,795, +3.6% versus FY 2018 Q3 |
| FY 2018 Q3 | Sep 30, 2018 | 5,596, −0.9% versus FY 2018 Q2 |
| FY 2018 Q2 | Jun 30, 2018 | 5,648, +11.0% versus FY 2018 Q1 |
| FY 2018 Q1 | Mar 31, 2018 | 5,088, −14.5% versus FY 2017 Q4 |
| FY 2017 Q4 | Dec 31, 2017 | 5,949, −8.6% versus FY 2017 Q3 |
| FY 2017 Q3 | Sep 30, 2017 | 6,512, −8.8% versus FY 2017 Q2 |
| FY 2017 Q2 | Jun 30, 2017 | 7,141, +9.8% versus FY 2017 Q1 |
| FY 2017 Q1 | Mar 31, 2017 | 6,505, −11.1% versus FY 2016 Q4 |
| FY 2016 Q4 | Dec 31, 2016 | 7,320, −2.4% versus FY 2016 Q3 |
| FY 2016 Q3 | Sep 30, 2016 | 7,500, −3.5% versus FY 2016 Q2 |
| FY 2016 Q2 | Jun 30, 2016 | 7,776, −0.2% versus FY 2016 Q1 |
| FY 2016 Q1 | Mar 31, 2016 | 7,794, −8.4% versus FY 2015 Q4 |
| FY 2015 Q4 | Dec 31, 2015 | 8,506, +2.5% versus FY 2015 Q3 |
| FY 2015 Q3 | Sep 30, 2015 | 8,295, +0.6% versus FY 2015 Q2 |
| FY 2015 Q2 | Jun 30, 2015 | 8,244, +8.6% versus FY 2015 Q1 |
| FY 2015 Q1 | Mar 31, 2015 | 7,594, +3.8% versus FY 2014 Q4 |
| FY 2014 Q4 | Dec 31, 2014 | 7,314, +21.1% versus FY 2014 Q3 |
| FY 2014 Q3 | Sep 30, 2014 | 6,041.832, −7.5% versus FY 2014 Q2 |
| FY 2014 Q2 | Jun 30, 2014 | 6,534.943, +30.7% versus FY 2014 Q1 |
| FY 2014 Q1 | Mar 31, 2014 | 4,998.956, +60.2% versus FY 2013 Q4 |
| FY 2013 Q4 | Dec 31, 2013 | 3,119.826, +12.1% versus FY 2013 Q3 |
| FY 2013 Q3 | Sep 30, 2013 | 2,782.833, +0.6% versus FY 2013 Q2 |
| FY 2013 Q2 | Jun 30, 2013 | 2,767.394, +9.3% versus FY 2013 Q1 |
| FY 2013 Q1 | Mar 31, 2013 | 2,531.635, −2.2% versus FY 2012 Q4 |
| FY 2012 Q4 | Dec 31, 2012 | 2,588.285, +6.7% versus FY 2012 Q3 |
| FY 2012 Q3 | Sep 30, 2012 | 2,426.597, +0.9% versus FY 2012 Q2 |
| FY 2012 Q2 | Jun 30, 2012 | 2,405.186, +5.4% versus FY 2012 Q1 |
| FY 2012 Q1 | Mar 31, 2012 | 2,282.449, +3.7% versus FY 2011 Q4 |
| FY 2011 Q4 | Dec 31, 2011 | 2,200.378, +3.7% versus FY 2011 Q3 |
| FY 2011 Q3 | Sep 30, 2011 | 2,121.66, −0.7% versus FY 2011 Q2 |
| FY 2011 Q2 | Jun 30, 2011 | 2,137.253, +11.0% versus FY 2011 Q1 |
| FY 2011 Q1 | Mar 31, 2011 | 1,926.094, −3.6% versus FY 2010 Q4 |
| FY 2010 Q4 | Dec 31, 2010 | 1,998.687, +3.1% versus FY 2010 Q3 |
| FY 2010 Q3 | Sep 30, 2010 | 1,937.656, +0.5% versus FY 2010 Q2 |
| FY 2010 Q2 | Jun 30, 2010 | 1,927.224, −7.6% versus FY 2010 Q1 |
| FY 2010 Q1 | Mar 31, 2010 | 2,085.853, +2.6% versus FY 2009 Q4 |
| FY 2009 Q4 | Dec 31, 2009 | 2,032.379, +12.8% versus FY 2009 Q3 |
| FY 2009 Q3 | Sep 30, 2009 | 1,801.389, +9.4% versus FY 2009 Q2 |
| FY 2009 Q2 | Jun 30, 2009 | 1,647.155, Change unavailable versus FY 2009 Q1 |
Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.
Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.
Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.